Pharmacotherapy with atomoxetine for US children and adolescents

Annals of Clinical Psychiatry

Volumn 19, Issue 3, 2007, Pages 175-180

  Bhatara, Vinod S ^a,c   Aparasu, Rajender R ^b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CENTRAL STIMULANT AGENT;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BIVARIATE ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTPATIENT DEPARTMENT; PHYSICIAN; PREDICTION; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; FEMALE; GEOGRAPHY; HEALTH SURVEYS; HUMANS; MALE; OUTPATIENTS; PROPYLAMINES; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 34548356924     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230701465244     Document Type: Article

References (27)

1. U.S. Food and Drug Administration: Strattera approved to treat ADHD. FDA Consum 2003; 37:4
2. Garces K: Atomoxetine for attention deficit/hyperactivity disorder. Issues Emerg Health Technol 2003; 46:1-4
3. Barton J: Atomoxetine: A new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child 2005; 90 (suppl1): 26-29
4. Kratochvil C, Wilens T, Greenhill L, Gao H, Baker K, Feldman P, Gelowitz D: Effects of long-term atomoxetine treatment for young children with attention deficit/ hyperactivity disorder. J Am Acad Child Adolsc Psychiatry 2006;45:919-927
5. Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M: Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder: The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45:642-657
6. Van Brunt DL, Johnston JA, Ye W, Pohl GM, Sun PJ, Sterling KL, Davis ME: Predictors of selecting atomoxetine therapy for children with Attention Deficit/ Hyperactivity Disorder. Pharmacotherapy 2005; 21:1541-1549
7. National Center for Health Statistics. 2004 National Ambulatory Medical Care Survey. Hyattsville, MD: United States Department of Health and Human Services, National Center for Health Statistics. Documentation available at: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NAMCS/ doc04.pdf Accessed September 14, 2006
8. National Center for Health Statistics. 2003 National Ambulatory Medical Care Survey. Hyattsville, MD: United States Department of Health and Human Services, National Center for Health Statistics. Documentation available at: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NAMCS/ doc03.pdf Accessed September 14, 2006
9. National Center for Health Statistics. 2003 National Hospital Ambulatory Medical Care Survey. Hyattsville, MD: United States Department of Health and Human Services, National Center for Health Statistics. Documentation available at:ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/ Dataset_Documentation/NHAMCS/doc03.pdf Accessed September 14, 2006
10. National Center for Health Statistics. 2004 National Hospital Ambulatory Medical Care Survey. Hyattsville, MD: United States Department of Health and Human Services, National Center for Health Statistics. Documentation available at:ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHAMCS/ doc04.pdf Accessed September 14, 2006
11. Koch H, Cambell W: The collection and processing of drug information. National Center for Health Statistics. Vital Health Stat 1982; 2(90)
12. Hing E, Gousen S, Shimizu I, Burt C: Guide to using masked design variables to estimate standard errors in public use files of the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey. Inquiry. 2003; 40:401-415
13. SAS: In: SAS-STAT users guide release, Changes and Enhancements, 8.0 Edition. SAS Institute, Inc. Cary, NC; 2001
14. Shah BV, Barnwell BG, Bieler GS: SUDAAN User's Manual, Release 7.5, Research Triangle Park, NC: Research Triangle Institute, 2002
15. US Department of Health and Human Services. Centers for Disease Control and Prevention: Health Care Financing Administration. International Classification of Diseases, 9th Revision, Clinical Modification. 6th Edition. 2004
16. Van Brunt D, Gibson P, Ramsey J, Obenchain R: Outpatient use of major antipsychotic drugs in ambulatory settings in the United States, 1997-2000. Med Gen Med 2003; 5: 16
17. Aparasu R, Bhatara V: Patterns and determinants of antipsychotic prescribing in children and adolescents: 2003-2004. Cur Med Res Opn 2007; 23:49-56
18. Andersen RM: A Behavioral model of families' use of health services. (Research Series 25). Center for Health Administration Studies. 1968: Chicago: University of Chicago.
19. Andersen RM: Revisiting the behavioral model and access to medical care: Does it matter? J Health Soc Behav 1995; 36:1-10
20. Sutton VK, Milton DR, Ruff DD, Sadowski K, Allen AJ: Efficacy of atomoxetine treatment for children and adolescents with attention deficit/hyperactivity disorder. Paper presented at the 51st Annual Meeting American Academy of Child and Adolescent Psychiatry, Washington, DC, October 19-24, 2004
21. Newcorn J. Spencer T, Biederman J, Milton D, Michelson D: Atomoxetine treatment in children and adolescents with attention deficit/ hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2005; 44:240-248
22. Kratochvil C, Newcorn J, Arnold LE, Duesenberg D, Emslie G, Quintina H, Sarks E, Wagner K, Gao H, Michelson D, Biederman J: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 2005; 44:915-924
23. Arnold LE, Aman M, Cook A, Witwer A, Hall K, Thompson S, Ramadan Y: Atomoxetine for hyperactivity in autism spectrum disorders. J Am Acad Child Adolesc Psychiatry 2006; 45:1196-1205.
24. Van Brunt DL, Johnston JA, Ye W, Pohl GM, O'Hara NN: Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD. Retrospective analysis of administrative claims data. J Mange Care Pharm 2006; 12. 230-238.
25. Spencer TJ, Farone SV, Michelson D, Adler L, Reimherr F, Glatt S, Beiderman J: Atomoexetine and adult attention deficit/ hyperactivity disorder: The effects of comorbidity. J Clin Psychiatry 2006; 67:415-420
26. Gibson AP, Bettinger TL, Patel NC, Crismon ML: Atomextine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother 2006; 40:1134-1142
27. Bhatara V, Feil M, Hoagwood K, Vitiello B, Zima B: Trends in combined pharmacotherapy with stimulants for children. Psychiatr Serv 2002; 53:244